Opsona Therapeutics
 | |
| Website |
www |
|---|---|
Opsona Therapeutics is a drug development company specialising in the human immune system and new drugs and vaccines to prevent and treat autoimmune/inflammatory conditions, cancers and infectious diseases.[1][2][3]
Based in Ireland, Opsona is a spin-out from Trinity College Dublin (TCD).[4] Ireland is ranked highly in the world in immunology research, and TCD has been at the forefront of the field.[5]
Opsona's research is primarily focused on the role of Toll-like receptors (TLRs) and TLR signalling in human innate immunity. The company was founded in 2004 by three immunologists:
- Professor Luke A. J. O'Neill[6]
- Professor Kingston Mills[7]
- Professor Dermot P. Kelleher[8]
Opsona's main investors are international and life-science focused:
- Inventages Venture Capital (Bahamas)[9]
- Seroba Bioventures (Ireland)
- GenenFund (United States)
- Enterprise Ireland (Ireland)[10]
References
- ↑ Article in the Irish Times
- ↑ Sunday Business Post article
- ↑ BusinessWeek company profile
- ↑ Article in the Irish Times
- ↑ Times Higher Educational Supplement - QS World University Rankings 2007
- ↑ Article in the Irish Examiner
- ↑ Article on the Trinity College Dublin website
- ↑ Article on the Trinity College Dublin website
- ↑ Article on Fierce Biotech
- ↑ PR Newswire article
This article is issued from Wikipedia - version of the 8/12/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.